Nov 4, 2024 • 7:00 am EST Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
Oct 29, 2024 • 8:00 am EDT Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
Oct 16, 2024 • 8:00 am EDT Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
Sep 26, 2024 • 8:00 am EDT Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
Sep 5, 2024 • 8:00 am EDT Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference
Aug 20, 2024 • 8:00 am EDT Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
Aug 6, 2024 • 8:00 am EDT Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Jul 30, 2024 • 8:50 am EDT Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
Jun 1, 2024 • 10:00 am EDT SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
May 30, 2024 • 8:00 am EDT Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference